Rituximab to prevent EBV-related cancer after organ transplant
Treatments studied
Part of Infections clinical trials.
This study tests whether a medication called rituximab can help prevent a type of cancer (PTLD) that sometimes develops in transplant patients whose body is fighting a reactivated virus (EBV). You may qualify if you've had an organ transplant, have high levels of EBV in your blood, and haven't yet developed this cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received a solid organ transplant (kidney, heart, liver, lung, or pancreas)
- You have high levels of EBV virus in your blood (≥1000 IU/mL) confirmed on two tests at least 1 week apart, within a 6-week window
- You do not have PTLD (a type of cancer) or a history of it, confirmed by imaging and biopsy if needed
- You are 18 years or older with a life expectancy of more than 6 months
- Your immunosuppression medications have been reduced or there is a documented reason they cannot be safely reduced
- If you have hepatitis B, C, or HIV, these infections must be controlled with appropriate treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a single dose of rituximab (a targeted antibody therapy) given after a donor stem cell transplant can reduce dangerous levels of the EBV virus in the blood. It aims to prevent a serious complication called PTLD (lymphoma-like disease) that sometimes occurs after transplant.
This trial tests whether one dose of rituximab (given around the time of transplant) can help prevent a first Epstein-Barr virus (EBV) infection and related abnormal lymph node or immune growths after kidney transplant. It is specifically for adults who are EBV-negative before receiving an EBV-positive donor kidney.
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
This trial tests a combination of two immunotherapy drugs (loncastuximab tesirine and rituximab) to treat a type of lymphoma (blood cancer) that develops after solid organ transplantation. The goal is to see if this treatment can help control the cancer while being safe for transplant patients.
This trial tests a new drug called epcoritamab for people whose PTLD (a type of lymphoma that can happen after an organ transplant) has come back or hasn't been helped by standard treatments. The goal is to see if epcoritamab can shrink or control the cancer.
This trial studies tafasitamab plus rituximab to treat a type of lymphoma called post-transplant lymphoproliferative disorder (PTLD) in adults after a solid organ transplant. It’s aimed at helping stop the PTLD when it can be measured and before you’ve had PTLD treatment beyond limited measures like steroid or reducing anti-rejection drugs.
Hear when a new Epstein-Barr Virus (EBV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.